

Roediger, Alexander

EFPIA Oncology Steering Committee



Alexander Roediger (1968), Swiss and German, MA and Executive Master of Business Administration, leads Oncology Policy at MSD for Europe, Middle East, Africa and Canada (EMEAC). In his current role he focuses on Oncology policy, i.e. health system financing, pricing and reimbursement and innovation policies. He is currently Chair of the EFPIA Oncology Steering Committee as well as Chair of the Healthcare Committee of the American Chamber of Commerce to the EU. He has a Master degree in Philosophy from the University of Zurich; in 2006 he received his Executive Master's Degree of Business Administration from the University of St. Gallen. Before joining MSD, he worked for UNICEF Switzerland and Helsana Insurances, a major health insurer in Switzerland.

Publications

Roediger A, Wilsdon T, Haderi A, Pendleton K, Azais B (2019), Competition between on-patent medicines in Europe ; Health Policy

Roediger A, Immonen-Charalambous K, Kujawa M, Sorensen K (2019), Nothing about me without me : why an EU health literacy strategy embracing the role of citizens and patients is needed ; Archives of Public Health, 77; 17

Wait S et al. (2017), Towards sustainable cancer care: Reducing inefficiencies, improving outcomes - A policy report from the All.Can initiative; Journal of Cancer Policy

Reiland JB, Freischem B, Roediger A (2017), What pricing and reimbursement policies to use for off-patent biologicals in Europe? - results from the second EBE biological medicines policy survey; rics and Biosimilars Initiative Journal (GaBI Journal). 2017;6(2):61-71

Roediger A (2015), Personalized health - health literacy in the context of personalized medicine (German); in: swiss academics reports, Gesundheitskompetenz in der Schweiz - Stand und Perspektiven; 2015; 10(4); p. 72-74

Roediger A (2015), mHealth – on the way to health literacy 2.0 (German); in: swiss academics reports, Gesundheitskompetenz in der Schweiz – Stand und Perspektiven; 2015; 10(4); p. 77-78

Roediger A, Acha V, Allin P, Bergunde S, Bisordi F (2015), What pricing and reimbursement policies to use for off-patent biologicals? – Results from the EBE 2014 biological medicines policy survey; Generics and Biosimilars Initiative Journal (GaBI Journal). 2015;4(1):17-24

Vromans L, Doyle G, Petak-Opel S, Roediger, Röttgermann M, Schlüssel E, Stetter E (2013), Shaping medicinal product information: a before and after study exploring physicians' perspectives on the summary of product characteristics; BMJ Open, 3